深圳市新产业生物医学工程股份有限公司2025年第三季度报告披露提示性公告

Core Points - The company has disclosed its third-quarter report for 2025, ensuring the accuracy and completeness of the information presented [1][6][35] - The board of directors held a meeting on October 28, 2025, to review and approve various proposals, including the third-quarter report and amendments to the company's articles of association [3][5][10] - The company plans to hold its first extraordinary general meeting of 2025 on November 13, 2025, to discuss several key proposals [28][41] Group 1: Board Meeting Details - The board meeting was conducted with all seven directors present, and the meeting adhered to legal and procedural requirements [3][4][9] - The board approved the third-quarter report, confirming that it reflects the company's actual situation without any misleading statements [6][35] - The board also approved amendments to the company's articles of association to enhance governance and operational standards [10][11] Group 2: Governance and Structural Changes - The company will add one employee representative director, increasing the board size to eight members, including three independent directors [10][11] - Various governance documents and rules were revised and approved, including the rules for the board of directors and the audit committee [12][13][14][15][16] - The monitoring committee will cease to exist as its functions will be transferred to the audit committee, following the new Company Law [38][39] Group 3: Financial and Operational Plans - The company has approved a total fixed asset investment budget of 756.7 million yuan for the fifth phase of its R&D production base in Pingshan, expected to be completed by the end of 2028 [26][27] - The company will utilize its own funds for the project, which includes construction costs for facilities and equipment [26] Group 4: Upcoming Meetings and Proposals - The first extraordinary general meeting of 2025 is scheduled for November 13, 2025, to discuss the approved proposals from the board meeting [28][41] - The board has proposed the election of a new independent director to fill the vacancy left by the resignation of an existing independent director [22][24]